Roche's Pegasys receives EU approval for the treatment of chronic hepatitis C in children five years of age and older

Roche announced today that the European Medicines Agency (EMA) has expanded the approval of Pegasys (peginterferon alfa-2a) plus ribavirin for the treatment of chronic hepatitis C virus (HCV). The new label includes children and adolescents five years of age and older, who have not received treatment and who have tested positive for the virus. Pegasys in combination with the antiviral ribavirin is the foundation of treatment for chronic HCV in adults. The medicine was first approved in the European Union over ten years ago.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Massoud O Abstract Introduction: The recent availability of highly effective hepatitis C medications, with a cure rate approaching 100%, has created a wide range of questions and uncertainties.Areas covered: The most recent data around hepatitis C virus (HCV) elimination will be reviewed. In addition, the impact of HCV cure or sustained virologic response (SVR) on the risk for hepatocellular carcinoma (HCC) development will be discussed. Although the terms 'SVR' and 'cure' are used interchangeably, there are little data to support that they are actually the same. In this review, we will shed some ligh...
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research
An intervention designed to help GP practices identify and refer patients for hepatitis C testing and treatment is both effective and cost-effective, research published in the BMJ has found.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
Authors: Priora M, Realmuto C, Parisi S, Ditto MC, Borrelli R, Peroni CL, Laganà A, Fusaro E Abstract Beyond the classic hepatic complications, hepatitis C (HCV) infection is considered as a systemic disease, since extrahepatic manifestations become clinically evident in 40 to 70% of the patients and it can frequently include rheumatic ones. Furthermore, HCV can promote the production of several autoantibodies, thus complicating the differential diagnosis between primitive and HCV- related rheumatic disorders. The recent development of direct-acting antivirals (DAA) against HCV has revolutionized the field, ...
Source: Minerva Gastroenterologica e Dietologica - Category: Gastroenterology Tags: Minerva Gastroenterol Dietol Source Type: research
Determining the rate of new hepatitis C virus (HCV) infections in a population is critical to monitoring progress toward HCV elimination and to appropriately guide control efforts. However, since HCV infections are most often initially asymptomatic, it is difficult to estimate the rate of new HCV infections without following HCV-uninfected people over time and repeatedly testing them for HCV infection. Here, we present a novel, resource-efficient method to estimate the rate of new HCV infections in a population using data from a single timepoint.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
Nima Iranpour, Gregory J. Dore, Marianne Martinello, Gail V. Matthews, Jason Grebely, Behzad Hajarizadeh During March 2016 to March 2017, a total of 935 individuals with HIV and hepatitis C co-infection initiated new highly curative hepatitis C treatment (direct-acting antiviral treatment), with 93% to 97% completing their prescribed treatment course. It is estimated that 41% of the total population with HIV and hepatitis C co-infection in Australia initiated hepatitis C direct-acting antiviral treatment during this time.
Source: Sexual Health - Category: Sexual Medicine Authors: Source Type: research
The cure of chronic hepatitis C infection has a major impact on the morbidity and mortality of infected patients. It is now clear that sustained virologic response improves overall survival and significantly reduces the risk of liver failure, fibrosis progression, need of liver transplantation, and incidence of hepatocellular carcinoma. Moreover, hepatitis C eradication improves a broad range of extrahepatic manifestations, such as dermatologic, neoplastic, cardiovascular, and endocrine, and improves quality of life.
Source: Gastroenterology Clinics of North America - Category: Gastroenterology Authors: Source Type: research
The World Health Organization has called for the elimination of hepatitis C virus (HCV) as a public health threat by 2030. Highly effective direct-acting antiviral agents provide the therapeutic tools required for elimination. In the absence of a vaccine, HCV elimination will require enhanced primary prevention and an increase in the proportions of people diagnosed and treated. Given that globally only 20% of people with chronic HCV are diagnosed, and around 5% have initiated HCV treatment, the task ahead is enormous. But, global public health needs optimism, and countries currently on track for HCV elimination provide a pathway forward.
Source: Gastroenterology Clinics of North America - Category: Gastroenterology Authors: Source Type: research
Authors: El-Daly UM, Saber MM, Abdellateif MS, Nassar HR, Namour AE, Ismail YM, Zekri AN Abstract BACKGROUND: Adipokines play an important role in the regulation of inflammation and tumor progression. AIM: Assessment of the possible role of adiponectin, leptin and visfatin in HCV associated hepatocellular carcinoma (HCC). METHODS: patients were classified into 85 patients with HCV associated HCC, 100 patients with chronic hepatitis C viral (HCV) infection compared to 50 normal control (NC) subjects. All subjects included in the study were assessed for HCV infection by seropositive HCV antibodies, as well as...
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
Authors: Huang P, Wang C, Zhuo L, Xia X, Yang S, Zhang J, Fan H, Wu J, Bin Y, Yue M, Zhang Y Abstract Background: The Fas cell surface death receptor (FAS) and Fas ligand (FASL) can participate in the apoptosis of immune cells and target cells infected with a virus through the FAS-FASL signaling pathway. The decoy receptor 3 (DCR3) can competitively inhibit the binding of FAS to FASL. Our aim is to investigate the effect of single nucleotide polymorphisms (SNPs) in FAS, FASL and DCR3 on hepatitis C virus (HCV) infection.Methods: Four SNPs (rs763110 in FASL, rs1324551 and rs2234767 in FAS and rs2257440 in DCR3) were...
Source: British Journal of Biomedical Science - Category: Laboratory Medicine Tags: Br J Biomed Sci Source Type: research
This study shows that ED HCV screening is feasible and that a small number of previously undiagnosed patients can be identified and linked to potentially life-changing care. PMID: 32211349 [PubMed - in process]
Source: Canadian Journal of Gastroenterology - Category: Gastroenterology Tags: Can J Gastroenterol Hepatol Source Type: research
More News: Children | European Medicines Agency (EMA) | Hepatitis | Hepatitis C | Pegasys | Pharmaceuticals